

Global Money Notes #10

Research Analysts

Zoltan Pozsar
212 538 3779
zoltan.pozsar@credit-suisse.com

Sterilization and the Fracking of Reserves

The defining fixed income market event of this year is shaping up to be the normalization of U.S. Treasury's cash balances. Normalization is set to drain close to \$400 billion of reserves from money markets during the fourth quarter, and the impact of that will be felt the world over: repo spreads, spreads to OIS and cross-currency bases are all set to widen, re-tracing most of the narrowing they've been through since January. According to our calculations, 3-month Libor-OIS could widen by at least 20 bps from current levels by year-end¹.

The "other" normalization – that of the Fed's balance sheet – is not a worry for this year. Even if it were to start now, its initial pace of \$10 billion a month is small compared to Treasury's removal of \$400 billion in reserves. We'll worry about balance sheet taper next summer, once its annual run-rate has accelerated to over \$100 billion. But that's still at least nine months away...

This issue of Global Money Notes introduces two new concepts: sterilization and the fracking of reserves. Both concepts are essential to understand how the draining of reserves and the destruction of reserves (through taper) affect the way repo and FX swap markets trade in the post-Basel III financial order.

Sterilization is a concept that's more familiar for investors in emerging markets than for investors that have grown up trading money markets in the G3 space. The same goes for central banks. For EM central banks, sterilization is always a deliberate step to tighten money markets. In contrast, the Fed lets sterilization run its course freely and doesn't link it to money markets conceptually one bit. That's a mistake, in our opinion.

\$1 trillion of reserves have been sterilized through various liability swaps on the Fed's balance sheet between January 1st, 2015 and December 31st, 2016. As sterilization increased, reserves declined, dollar liquidity suffered, and term spreads in money markets widened. To be able to settle, the system started to "frack" U.S. banks' HQLA portfolios for reserves. But like fracking shale formations, that process is costly and messy from a Basel III perspective.

From a funding perspective, destroying reserves through balance sheet taper is the same as sterilizing reserves through the normalization of Treasury's cash balances. And if the fallout from the latter will mean a replay of the spread widening we have seen in dollar funding markets late last year, the Fed may even re-consider the timing, pace and endpoint of its tapering plans...

This issue of Global Money Notes has six parts to it.

Part one discusses how the Fed has been sterilizing reserves through its increased offering of overnight liquidity services to institutions. Part two discusses the concept of fracking HQLA portfolios for reserves. Part three discusses the concept of the quarter-end turn premium. Part four identifies J.P. Morgan's reserves-rich HQLA portfolio as the Bakken Shale of global financial system and the bank as the system's lender of next-to-last resort. Part five discusses what happens when sterilization goes into reverse. Finally, part six concludes with what the normalization of Treasury's cash balances means for Libor-OIS.

¹ For the underlying rationale, please see page 18.

Part 1 – Basel III and the Sterilization of Reserves

In the post-Basel III financial order, the Manager of the System Open Market Account (SOMA) became the world's most powerful bank treasurer.

With great power comes great responsibility. That includes broadening the discourse about the Fed's role in money markets beyond the overnight point and asking the question of whether at times the Fed should police term spreads by stepping in for balance sheet constrained banks as a market maker even outside of crisis times. The stakes are no less than the Fed's control over the global monetary transmission process and the maintenance of some semblance of bounded parity between the cost of onshore dollars and Eurodollars.

Part of the discussion about the Fed's balance sheet has revolved around the composition of the SOMA portfolio, the risks that a large amount of reserves could pose to the Fed's ability to control the fed funds rate, and how these risks could be mitigated through the draining of reserves via the overnight RRP facility. More recently, discussion turned to the reduction of the SOMA portfolio through the tapering of Treasury and MBS reinvestments.

The biggest theme, however, got entirely unnoticed. And that theme has to do with the Fed's growing role as a bank for institutions – a direct result of Basel III incentivizing banks to push institutional deposits off their books and onto the balance sheet of the sovereign.

The Fed's increased offering of overnight liquidity services to a growing customer base is driving massive shifts on the liability side of its balance sheet. Gone are the days when currency was the Fed's dominant liability and reserves a fragment of its balance sheet:

- (1) U.S. Treasury no longer keeps its excess cash with private banks, but at its account at the Fed. Its balances can run as high as \$400 billion (see Figure A1).
- (2) Foreign central banks have moved their cash from private banks as well, and keep about \$250 billion on deposit at the Fed's foreign repo pool (see Figure A2).²
- (3) Money funds became habitual users of the o/n RRP facility, placing \$150 billion with the Fed on an average day and double that on quarter-ends (see Figure A3).
- (4) Central counterparties are the latest addition to the Fed's growing customer base, with ICE and CME keeping a combined \$100 billion at the Fed (see Figure A4).

Figure 1 shows the sea change in the Fed's balance sheet since the financial crisis. Currency outstanding doubled; reserves went from a negligible item to a dominant item; and liquidity services provided to institutional cash investors ranging from U.S. Treasury, foreign central banks, money funds and CCPs grew from nothing to \$800 billion at the peak.³

Figures 2 and 3 show how for every dollar moved from a bank to the Fed directly, reserves fall by a dollar and balances in institutional liquidity accounts increase by a dollar. Far from being an active driver of these flows and associated liability swaps, the Fed has been a passive accommodator of them. As banks pruned their books to get Basel III compliant, customers looked to park their liquidity elsewhere and the Fed welcomed them.


The unifying theme across these flows is that every time the above institutions move their funds from a bank to the Fed, reserves are drained from the banking system and funds move from entities that trade reserves (banks) to an entity that does not (the Fed). In previous issues of Global Money Notes (see [here](#)) we have referred to these accounts as "funding black holes" – the institutional equivalents of keeping cash under the mattress.⁴

² Foreign central banks also moved some of their dollar reserves from U.S. Treasury bills to the Fed's foreign repo pool (see [here](#)).

³ The volume of overnight liquidity services provided to institutional cash investors fluctuates over time. It has been increasing on a trend-basis since 2015, and peaked at \$800 billion in November, 2016. In recent months, volumes fell to a lower \$250 billion.


⁴ Increases in currency outstanding have a similar impact on reserves. Every time a bank deposit is converted to currency, the Fed swaps reserves into currency (this is true whether deposits are withdrawn through visits to an ATM or by shifting one's liquidity to a safe at a freeport in Geneva). The result is fewer claims on banks and more on the Fed directly (see Figure 4).

Figure 1: The Fed's Increased Service Offering




Source: Federal Reserve, Credit Suisse

Figure 2: Reserves and Overnight Liquidity Services



Source: Federal Reserve, Credit Suisse

Figure 3: Swaps of IOUs



Source: Credit Suisse

Because unlike banks, the Fed doesn't trade the funds it takes in via funding black holes, when the amount of reserves declines, term money markets tighten. This is especially true in the FX swap market where the amount of reserves held by banks at the Fed determines the amount of U.S. dollars that banks can swap for yen, euros, pounds and Swiss francs in the form of reserves at other central banks without having to sell or repo something first.

Reserves weren't always the grease to FX swap transactions. Before the crisis, banks stored their liquidity in interbank money markets, and endless arbitrage across interbank markets ensured parity across OIS, repo, Libor and FX swap implied funding curves. Arbitrage involves borrowing in one market and lending in another. Lending involves the creation of deposits, and interbank lending involves the creation of interbank deposits. Arbitrage involving FX swaps were typically settled using interbank deposits, and, if deposits were insufficient, one could always repo bonds cheaply by calling up a dealer.

No longer. Post-Base III, banks keep their liquidity with the sovereign, not other banks, and reserves, not interbank deposits are the system's main settlement medium (see [here](#)).⁵

FX swaps used to mean deposit swaps. Now they mean reserve swaps.

When the amount of reserves declines, banks increase their reliance on repos to settle. But that is not without costs. In a regime where balance sheet is rationed repos are costly, and the more the banking system relies on repos to settle FX swap trades, the farther FX swap implied rates drift from the OIS curve and the wider the cross-currency basis.⁶

Investors who have grown up trading emerging markets (EM) are more familiar with the impact that central banks' liability swaps can have on conditions in money markets than investors who have grown up trading G3 money markets. Effectively what we are saying is that draining reserves is the equivalent of sterilization operations by EM central banks. Think of the PBoC buying dollars by creating yuans and then sterilizing yuans by swapping them into central bank bills. The Fed swapping reserves for other liabilities is the same.

EM central banks' sterilization operations are always deliberate. They are aimed at tying up funds to keep them from fanning excessively easy conditions in money markets and excessive lending growth. But the Fed does not think of reserves getting drained or swapped into other liabilities as sterilization and lets liability swaps run their course freely. Left unaddressed, the net impact of sterilizing reserves are tighter funding conditions, similar to the one that we have seen gradually emerge in the FX swap market since 2015.

⁵ In a post-Base III financial order, banks only trade with each other on a secured basis, not unsecured. That means that secured repos and FX swaps replaced unsecured fed funds and interbank deposits as the instruments through which the system settles.

⁶ See Parts II and III for details.

Part 2 – Sterilization and the Fracking of Reserves

The sterilization of reserves in the U.S. financial system started on January 1st, 2015 – the go-live date of Basel III and the start of banks' efforts to prune their balance sheets of unwanted institutional deposits. Sterilization commenced only weeks after the Fed ended QE and the corresponding injection of reserves to the financial system in November 2014. Flows related to money fund reform drove a second wave of sterilization during 2016, but during this episode it was flows initiated by money fund investors rather than banks that drove the swap of reserves to other liabilities. By the end of 2016, the cumulative amount of reserves that have been sterilized has reached \$1 trillion (see Figure 4), and FX swap implied costs of dollar funding rose to levels that are typical of crisis times (see Figure 5).⁷

Sterilization impacts FX swap-implied rates through two channels: (1) the gradual shift in the funding of intra-quarter FX swap trades away from arbitrage to “fracking” reserves in U.S. banks' HQLA portfolios, and (2) the quarter-end turn premium. The first channel we discuss in the remainder of this section, and the second we discuss in the following section.

Figure 6 shows the hierarchy of market making in the FX swap market. It shows how market making can shift from broker-dealers to banks, from foreign banks to U.S. banks and from U.S. banks doing arbitrage to fracking their HQLA portfolios in normal times, and from fracking to the Fed in crisis times. It highlights four distinct levels of intermediation.

Level 1 intermediation involves broker-dealers that run matched FX swap books and intermediate between accounts that are long dollars and wish to lend dollars via FX swaps, and accounts that are short dollars and wish to hedge their short positions via FX swaps. Dealers either sit in a bank or a bank holding company. Because they run matched books, dealers' market making activity has a neutral impact on their parent's liquidity position. But matched books seldom clear markets, and bridging imbalances in order flows is always for a parent bank's treasurer to decide one level higher in the hierarchy. It is at these higher decision-making levels where the cross-currency basis gets determined through arbitrage.

Level 2 intermediation involves foreign banks bridging imbalances through arbitrage by tapping unsecured CD and CP markets. Because foreign banks report balance sheet only on quarter-ends, intra-quarter, their balance sheets are boundless. That means that for trades shorter than three months, foreign banks will lend dollars even at very low spreads.

For trades three months or longer, the picture is more complicated. Trades shorter than three months can always be erased from balance sheets before reporting dates – e.g., overnight trades can be turned off from one day to another, and most term trades can be structured such that they mature before quarter-ends. But trades three months or longer always stay on the books on quarter-ends. Because they are reported, they use equity, and because they use equity, they better not dilute return-on-equity (RoE) targets. Most foreign banks have a leverage ratio of only 3% which means that for an RoE target of 15%, a three-month FX swap trade must earn a spread of about 45 bps at a bare-bone minimum.


Intra-quarter balance sheet galore and relatively cheap balance sheets notwithstanding, foreign banks' ability to step in as arbitrageurs is always a function of conditions in wholesale funding markets. When markets are under strain, activity shifts one level higher.

Level 3 intermediation involves U.S. money center banks stepping in for foreign banks. Unlike foreign banks, which only have access to at times volatile wholesale funding, U.S. banks have access to more stable funding such as retail deposits or FHLB advances. Access to state sponsored funding means that U.S. banks can get dollars when others can't.

But stable funding does not mean cheap balance sheets. Because U.S. banks have double the leverage ratio of most foreign banks, and because U.S. banks report balance sheet every day and not just on quarter-ends like most foreign banks, the minimum spreads at which they step in to make markets are much wider than those of foreign banks.


⁷ Also see Figure A5 and A6 in the appendix.

Figure 4: Waves of Sterilization




Source: Federal Reserve, Credit Suisse

Figure 5: The Mother of All Bases



Source: the BLOOMBERG PROFESSIONAL™ service, Credit Suisse

Figure 6: Hierarchy at the Outer Rim



Source: Credit Suisse

For a U.S. bank subject to a 6% leverage ratio (eSLR) and a 15% return-on-equity target, three-month spreads are at least 100 bps. At face value, the math works out to 90 bps, but U.S. banks manage to a stressed SLR, not to mention their outsized [G-SIB surcharges](#).

Level 4 intermediation involves the Fed stepping in as the system's lender of last resort at OIS + 50 bps during times of systemic credit stress. But it need not be the case that the Fed lends via the swap lines only when private markets freeze due to credit risk concerns. The Fed has neither funding nor balance sheet constraints. Whether it should step in to police term spreads at OIS + 50 bps in normal times is up to the FOMC to decide – and fostering debate about that is the job of the Manager of the System Open Market Account.

Prime money fund reform was a watershed event in that it pushed arbitrage volumes in the FX swap market away from cheap foreign to expensive U.S. balance sheets (see [here](#)). The flow of funds away from prime to government funds, and from the CD and CP market to FHLB's advances reduced the weight of foreign banks' intra-quarter arbitrage volumes and increased those of U.S. banks. Lower funding costs through advances notwithstanding, the wider spread targets of U.S. banks led to cross-currency bases drifting structurally wider.

Putting trades on for 100 bps assumes a simple arbitrage where a bank borrows reserves to lend dollars via FX swaps – a trade which would only impact banks' leverage ratios. But money fund reform also meant the sterilization of reserves, and sterilization meant that U.S. banks had to "drill" into their HQLA portfolios to meet the market's needs for dollars. By lending reserves from their HQLA portfolios, banks swap dollar liquidity for liquidity in other currencies (in the form of deposits at other central banks). This can worsen a range of Basel metrics. Fixing these requires balance sheets which can increase spreads further.

In a way, lending dollars via arbitrage is like drilling oil in Saudi Arabia and lending dollars from HQLA portfolios is like fracking – cheap and easy versus expensive and messy. Fracking is best understood through the quarter-end turn premium, which we discuss next.

Part 3 – Sterilization and the Turn Premium

Money market rates used to be a simple function of Fed expectations and a term premium. Now we need to add a turn premium – the premium that flares up around quarter-end turns. Understanding the turn premium is important because expectations for the size of *future* quarter-end turns can account for up to ½ of the cross-currency basis at longer tenors *today*.

Understanding the turn premium begins with understanding the role of reserves in the post-Basel III financial order, where balance sheet is rationed and repo costly and scarce. The turn premium exists because foreign banks turn off their arbitrage activities around quarter-end reporting dates. When arbitrage is off, money funds that typically lend to foreign banks, lend to the Fed via o/n RRP instead. When o/n RRP take-up spikes, the volume of reserves falls and dollars get scarce. U.S. banks fill the void by fracking their HQLA portfolios for reserves. But U.S. banks are subject to tougher Basel III ratios and liquidity stress tests than foreign banks, and the price at which U.S. banks lend reserves via FX swaps depends on the degree to which the marginal trade hurts their Basel metrics. That, in turn, depends on the amount of reserves in U.S. banks' HQLA portfolios. Figure 7 shows what quarter-ends look like when reserves are abundant and when they are scarce.


In the first example, a U.S. bank starts with reserves on the asset side of its balance sheet, funded with retail deposits. The bank then lends dollars through an FX swap transaction (step 1): it books an FX swap loan on the asset side and a deposit on the liability side, which expands its balance sheet. When the borrowing entity withdraws the dollars, the bank funds the withdrawal by wiring reserves to the reserve account of the recipient bank (step 2). Once the flows have settled, the bank files its end-of-day balance sheet snapshot (step 3): its SLR is unchanged, but its LCR is qualitatively different. Its LCR is different because the FX swap trade reduced the bank's dollar liquidity (fewer reserves at the Fed) and increased the bank's yen liquidity (more reserves at the BoJ). The Fed may or may not have issues with this. If the bank that lent the dollars keeps most of its dollar HQLA in the form of reserves at the Fed, swapping some dollars for yen (reserves for reserves) may not raise eyebrows. But if the bank that lent dollars keeps most of its dollar HQLA in the form of U.S. Treasuries or MBS, the swapping of dollars for yen may not be possible without taking some remedial action – the Fed may require the bank to increase the amount of reserves in its HQLA portfolio to restore its dollar liquidity to the starting point (step 4). In this case, the FX swap trade is not balance sheet neutral. The expansion of the HQLA portfolio increases the bank's balance sheet and brings it closer to the SLR limit.⁸

In the second example, a U.S. bank has Treasuries instead of reserves in its HQLA portfolio. Like before, the bank lends dollars to a borrowing entity through an FX swap trade (step 1), and the borrowing entity withdraws its dollar deposit to spend it on something. But the way the bank funds the withdrawal of dollars is different from before. Treasuries are more liquid than most securities, but are less liquid than reserves – they cannot be used for settlement (step 2). The bank lending the dollars cannot fund the withdrawal of dollars unless it turns Treasuries into cash through the repo market.⁹ This funding step represents an extra cost that was not there in the previous example. Once the trade has settled, the bank files its end-of-day balance sheet report: its SLR got worse and its LCR got worse too (step 3). Its SLR is worse because it used balance sheet to fund the withdrawal of dollars. Its LCR is worse too because repos encumber bonds and only unencumbered bonds count as HQLA. To fix its LCR, the bank has to raise unsecured funding and buy more Treasuries (step 4). This funding step represents yet another extra cost that was not there in the prior example. By the time this is done, the bank's balance sheet increased by two extra layers, leaving only half the slack as before. This will raise the price of the next FX swap trade.

⁸ We have little visibility into the philosophy with which the Fed stress-tests banks' HQLA portfolios. Whether the FX swap trade described above would pass from an LCR perspective is determined through the Fed's CLAR process. The point is that FX swap trades that are funded secured (not unsecured) impact banks' LCR, which in turn must be taken into account when pricing them.

⁹ In a post-Basel III financial order, banks only trade with each other on a secured basis, not unsecured. That means that secured repos and FX swaps replaced unsecured fed funds and interbank deposits as the instruments through which the system settles.

Figure 7: Fracking is Messy!



Source: Credit Suisse

Figure 8 shows what sterilization does to one-week forward points around quarter-ends. As sterilization grows, the turn premium grows too, and as the turn premium grows, the cross-currency basis widens. The turn premium grows because fewer reserves make it harder for U.S. banks to step in for foreign banks without having to take steps to protect their Basel III ratios. As the above examples explained, starting liquidity positions matter – stepping in as market maker is much easier when HQLA portfolios are flush with reserves.

Figure 9 shows what sterilization does to the GCF repo rate. As sterilization grows, the turn premium grows too as the quarter-end netting needs of dealers are exacerbated by U.S. banks tapping the GCF market to fund FX swap trades. The spread between o/n GCF and o/n tri-party repo rates grows progressively wider as well, which is a sign of reserves getting more scarce in the interbank money market. In addition, o/n tri-party rates tend to trade at a growing spread over the o/n RRP rate as dealers attempt to take in more cash from government money funds to lend into the o/n GCF market which trades at a premium.

These dynamics have an important message for anyone looking for the o/n fed funds market to trade tighter as reserves are drained: stop expecting that, it will never happen!

Unsecured markets like the fed funds (FF) market are dead under Basel III as banks no longer trade with each other on an unsecured basis. Only secured money markets survive. Locally, banks settle via repos. Globally they settle via FX swaps. The strains you're waiting for in the FF market are right in front of your eyes in the repo and FX swap markets.


These dynamics have an important message for the Fed as well. Reserves are not excess. Dropping the E from IOER is progress (see Simon Potter's speech [here](#) versus [here](#)), but talking the talk ain't the same as walking the talk. Taper with care, or the dollar gets scarce!

If the dollar gets scarce, the Fed may need to inject reserves back into the system through open market operation on the asset side of its balance sheet much sooner than it thinks.

To ease funding conditions, the Fed would have to inject reserves back into the system, for example through the dollar swap lines. Doing so would involve booking dollar loans at OIS + 50 bps in the form of FX swaps on the asset side of the balance sheet, and creating those dollars in the form of reserves on the liability side of the balance sheet (see Figure 10).


In other words, to keep conditions in the FX swap markets unchanged, market making activities on the liability side of the Fed's balance sheet which drain reserves, should have a symmetrical counterpart on the asset side ready to add reserves back in as needed. At the very least, this would involve "relaxing" access to the swap lines on quarter-ends, to offset some of the funding pressures that come from the recurring spikes in RRP take-up.

Figure 8: Sterilization and the Turn Premium in the FX Swap Market




Source: the BLOOMBERG PROFESSIONAL™ service, Credit Suisse

Figure 9: Sterilization and the Turn Premium in the GCF Repo Market



Source: the BLOOMBERG PROFESSIONAL™ service, Credit Suisse

Figure 10: Neutralizing Sterilization



Source: Credit Suisse

Part 4 – Sterilization and J.P. Morgan

For the moment, the Fed operates squarely as a one-sided money dealer: it makes markets only on the liability side of its balance sheet but not on the asset side. Figure 11 shows the Fed’s one-sided nature as market maker and the volume of sterilization in context.

First, market making in overnight liquidity services which drain reserves (the light blue line) are currently not being neutralized by activities which would add reserves back in either via repos, FX swaps or discount window lending (see the dark blue, red and orange lines).

Second, the amount of reserves sterilized to date is by no means trivial – it is close to the amount of reserves added through either the discount window or the swap lines in 2008. The injection of reserves through the swap lines in 2008 substituted for the breakdown of interbank markets – reserves replaced interbank deposits as the settlement medium. But today, reserves are the system’s settlement medium. Draining as much of them as the amount added at the height of the crisis is bound to have a significant market impact, especially considering that the size of the FX swap market doubled since then (see [here](#)).

The reason why the Fed remains a one-sided money dealer is that its guiding philosophy about liquidity provision remains anchored by the view that it should add reserves only during crisis times when markets cease to exist due to a flare-up of credit risk concerns. Liquidity provision in order to police the range within which FX swap markets trade in normal times – i.e., outside of crises – is not yet a stated aim of the Fed, and so when the OIS + 50 bps bound for FX swap implied rates is breached, the Fed does nothing about it.


Short of a public backstop to the FX swap market, only private backstops are available in normal times. In turn, the spreads at which private backstops kick in are to a large extent determined by the parameters with which the Fed chose to apply Basel III to U.S. banks. As our discussion above has shown, these private spreads are at least 100 bps, which has implications for how wide cross-currency bases can go in times of stress (see Figure 12).

By being unwilling to step in to police the cross-currency basis at OIS + 50 bps, the Fed leaves it to large U.S. banks to act as the world’s dollar lenders of next-to-last resort, and to one large U.S. bank in particular – J.P. Morgan Chase Bank, N.A. of Columbus, OH.

Unlike the Manager of the SOMA, J.P. Morgan cannot create reserves out of thin air, but it holds far more reserves than any other bank in the financial system (see Figure 13). With slight exaggeration, J.P. Morgan has twice as many reserves at the Fed as the second most reserve-rich U.S. G-SIB (Wells Fargo), four times as many as the third most reserve-rich U.S. G-SIB (Bank of America), and more than all foreign G-SIBs combined.


Having a lot of reserves does not mean being a money market Samaritan. The game is to figure out where less liquid banks would lend, and lend just below that rate (see Figure 14). As discussed above, the less liquid a bank’s HQLA portfolio, the harder it is to lend reserves via FX swaps and the higher the price charged for dollars. J.P. Morgan is the closest to the example of a bank that can frack its HQLA portfolio without messing up any of its Basel III metrics. Think of J.P. Morgan’s HQLA portfolio as the “Bakken Shale” of the global financial system, and the bank as the system’s *de facto* lender of next-to-last resort.

Figure 11: Sterilization in Context



Source: Federal Reserve, Credit Suisse


Figure 12: Public vs. Private Backstops



Source: the BLOOMBERG PROFESSIONAL™ service, Credit Suisse

Figure 13: J.P. Morgan's Absolute Dominance


2017Q1, \$ billion



Source: Federal Reserve, FFIEC, Credit Suisse

Figure 14: J.P. Morgan's Relative Dominance

2017Q1, percent



Source: FFIEC, BIS, Credit Suisse

Part 5 – Sterilization in Reverse

When J.P. Morgan’s spreads are tested, everyone’s on edge – including the Fed. After all, what spreads of over 100 bps over OIS mean is that in some regions of the world, dollars are going for a price that’s way outside the Fed’s desired range for FX swap implied rates, and imply at least four additional hikes over and above what’s actually been administered.

Calls for a more liberal access to the swap lines and the Fed to step in as market maker to enforce the OIS + 50 bps bound were intense last year in the wake of money fund reform. But the Fed remained silent about the widening of cross-currency bases and the tightness of global dollar funding markets in general. Central bankers at the [BoJ](#), the [RBA](#) and the [BIS](#) cared about the basis and gave smart speeches, but there were no speeches from the Fed.

A good bank treasurer knows about every major shift to occur on his bank’s balance sheet – weeks in advance. Maybe the reason why the Fed decided to hold off on deploying the FX swap lines last fall was that it knew full well that due to the looming debt ceiling, its largest customer was about to run down its cash balances. That in turn would mean an injection of about \$400 billion of reserves into the banking system – sterilization in reverse.

Figure 15 shows what happens when reserves enter the system via reverse sterilization. When U.S. Treasury ran down its cash balances from \$400 to \$50 billion late last year (see Figure A1), the supply of bills only fell by \$100 billion. This means that most of the decline in TGA balances came from Treasury paying for social programs (UI claims, etc.), the wages and salaries of federal employees, and the vendors of the federal government.

The accounts of the individuals and businesses that received these payments are mostly with large U.S. banks. As the federal payments trickled in, U.S. banks’ balance sheets increased on both sides. On the asset side, banks credited customer deposits with the funds received from the federal government. On the liability side, the Fed credited banks’ reserve accounts and debited the TGA every time the U.S. Treasury made a payment.


This type of balance sheet expansion is the best any bank can wish for. The types of liabilities that increased are retail and corporate operating deposits. These deposits cost nothing as they are noninterest-bearing. They also have very low HQLA requirements. That means that they can be used to fund whatever. The types of assets that increased are reserves which are super liquid. That means that they can be lent whenever, wherever.

How do you spend \$250 billion of reserves quickly as a money center bank? By lending them in the richest corner of the global money market, which is the FX swap market...

A good treasurer knows that whether reserves are injected through the swap lines or U.S. Treasury spending down its cash balances is the same thing. Either way, the banking system would end up with more reserves and global funding conditions would ease.

The way reserves flow into the FX swap market from reverse sterilization is similar to the way reserves flow into the FX swap market from the activation of the dollar swap lines (compare Figure 15 to Figure 10 on page 11). But there are also some crucial differences.

Figure 15: Covert Liquidity Injection



Source: Credit Suisse

Adding reserves via reverse sterilization happens passively as the Fed accommodates customers' flows on its balance sheet – just like any private bank would. In contrast, adding reserves via the dollar swap lines happens with the active participation of the Fed – like giving a speech on eliminating stigma associated with the use the dollar swap lines.

Adding reserves through reverse sterilization means that U.S. banks lend on reserves via FX swaps, and adding reserves via the swap lines means that the Fed lends reserves via FX swaps. Banks have balance sheet constraints and a minimum spread target of 100 bps, but the Fed has no balance sheet constraints and could lend at spreads as low as 50 bps.

Most importantly, an increase in noninterest-bearing deposits due to reverse sterilization means that the marginal cost of dollar funding for U.S. banks changes from OIS-like levels to zero, which can bleed through to the cross-currency basis. An increase in reserves and zero-interest deposits at all major U.S. banks also means that the value of J.P. Morgan's HQLA portfolio and its CIO's ability to police the cross-currency basis diminishes, similar to how the value of the Bakken Shale diminishes when Saudi Arabia floods the oil market.

Figure 16 shows what the surge in zero-interest funding did to the FX swap market. Using the \$/¥ cross as our benchmark, three-month FX swap implied rates have been trading around 1.50 percent despite the fact that the Fed hiked rates three times since December. How come? Because U.S. banks did not have to raise reserves via OIS-linked funding. Noninterest-bearing deposits did the trick. More reserves also meant easier fracking on quarter-ends, as the decline in turn premia year-to-date suggests (see Figures 8 and 9).

If the cross-currency basis could speak...

...it would scream that there is more to understanding it than demand outstripping supply and Basel III limiting banks' ability to fill the gap via arbitrage. The world is more nuanced.

Figure 17 shows the five phases the FX swap market has gone through since 2014. What's been constant since 2014 was growing monetary policy divergence between the U.S. and other markets. What's been in flux was the plumbing of the global financial system and the absolute amount of U.S. dollars sloshing around in the form of reserves at the Fed.

Phase 1, which lasted from January 2014 to September 2015, was driven by foreign banks getting Basel III compliant and adjusting their spread targets for term FX swap trades.

Phase 2, which lasted from October 2015 to April 2016, was driven by Treasury draining \$300 billion in reserves from the system and the impact that had on the turn premium.


Phase 3, which lasted from April 2016 to October 2016, was driven by money fund reform pushing arbitrage flows away from cheap foreign balance sheets to expensive U.S. ones. In the case of the \$/¥ basis, it was most definitely not driven by Japanese banks tapping the FX swap market – we know this from data from the Bank of Japan which shows no increase in Japanese banks' bid for dollars via FX swaps over this period (see Figure 18).

Phase 4, which spanned the fourth quarter of 2016, was very good times for J.P. Morgan. Fracking the Bakken Shale became RoE positive and lending dollars from it turned markets. We learned that the next time the three-month \$/¥ basis widens to over 100 bps over OIS, it'll soon start to narrow. When it comes to cross-currency bases, do not fight J.P. Morgan!

Phase 5, which is the regime we've been in since January 2017, was driven by Treasury burning through its cash balances. \$300 billion in reverse sterilization stole J.P. Morgan's thunder just as Saudi Arabia flooding the world with oil stole the Bakken Shale's thunder.


Japan's bid for U.S. fixed income is still there, so the story that reduced hedging needs depressed the basis is hard to believe. Banks drove the net sale of U.S. dollar assets since November – lifers and pension funds did not. And as Figure 18 shows, the corresponding decline in Japan's bid for dollars was in repo and not in FX swaps. Ditto for the story that real money accounts coming out of the weeds when the basis was wide was what turned the market. If that were true, those accounts should no longer be lending at current spreads and their absence should definitely have reversed the basis. Details matter!

Figure 16: Getting Dollars at Off-Market Prices




Source: the BLOOMBERG PROFESSIONAL™ service, Credit Suisse

Figure 17: If the Cross-Currency Basis Could Speak...




Source: the BLOOMBERG PROFESSIONAL™ service, Credit Suisse

Figure 18: Japanese Banks Did Not Drive the \$/¥ Basis Wider...



Source: Bank of Japan, Credit Suisse

Figure 19: Reverse-Engineering Libor



Source: the BLOOMBERG PROFESSIONAL™ service, Credit Suisse

Conclusions – Sterilization Redux

Sterilization will soon rear its ugly head again.

We know from the most recent Refunding Statement of the U.S. Treasury (see [here](#)), that TGA balances will be back up to \$400 billion by the end of 2017. Draining that much in reserves will reverse most of the easing that we have seen in funding markets this year.

Fewer reserves mean more fracking and more fracking means wider cross-currency bases. Fewer reserves also mean tougher quarter-ends and greater turn premia, which, in turn, mean even wider cross-currency bases. Treasury normalizing its cash balances is bound to sap global funding markets, and the FX swap market will bear the brunt of normalization.

FX swap-implied rates have great relevance for banks' U.S. dollar Libor submissions in a post-Basel III financial order, and an even greater relevance post-money fund reform.

Banks no longer trade with each other on an unsecured basis under Basel III and so submissions for interbank-offered rates should mostly reflect secured transactions. For a while, banks could substitute unsecured interbank transactions for unsecured transactions with money funds in the CD and CP market. But money fund reform reduced the depth of those markets, which hurt banks' ability to issue unsecured paper reliably and frequently.

Following the guidelines set forth in [The Wheatley Review of Libor](#) (see Box 4.B), banks next switched to the FX swap market as a reliable source of inputs for Libor submissions. As such, the weight of FX swap-implied rates in model-driven submission likely increased since last October. Unfortunately, there is no way to test this assumption, as in June 2016, ICE stopped the publication of individual panel members' U.S. dollar Libor submissions.

Figure 19 shows our quick attempt to reverse-engineer U.S. dollar Libor submissions using FX swap-implied rates. The results are not perfect, but they seem encouraging.¹⁰

Establishing a link between FX swap-implied rates and U.S. dollar Libor is important, because if sterilization tightens the FX swap market it also makes Libor-OIS widen. In our view, Treasury normalizing its cash balances will cause funding spreads to widen by 20 bps from current levels by the end of 2017, with more to come during the first quarter as expectations for turn premia in FX forwards get re-priced as reserves get scarce again.

The Fed's [plan](#) to start shrinking its balance sheet later this year will exacerbate these trends as 2018 progresses – from the perspective of funding markets, destroying reserves through balance sheet taper is the same as sterilizing reserves through liability swaps. But for the rest of 2017, the fixed income market event to focus on is not balance sheet taper, but the normalization of Treasury's cash balances. And if the fallout from the latter will mean a replay of the spread widening we've seen in global dollar funding markets late last year, the Fed may even re-consider the timing, pace and endpoint of its grand tapering plan.

As Mike Tyson would say: *"Everyone has a plan 'till they get punched in the mouth"...*

One thing is for sure: having loads of reserves means being able to harvest the option value of cash in a post-Basel III world where reserves determine how money markets trade. If there is one bank that's set to benefit from sterilization or taper, that bank is J.P Morgan.


If there is one thing that everyone who trades the basis in a post-Basel III world should do is to follow closely how U.S. G-SIBs' HQLA portfolios and Basel III metrics evolve over time, for reading that stuff may just be as important as Fed watching used to be in the past!

Reserves matter. He who has the most, controls the market for liquidity...

¹⁰ Our back of the envelope calculation is based on the following assumptions. Banks submit either OIS, repo or FX swap-implied funding levels. Of the 17 panel members, only 9 remain once the top four and bottom four submissions are thrown out. We assign a weight of one for GCF repo-based submissions, two for OIS-based submissions, three for FX swap-implied rates derived from GBP, two for FX swap-implied rates derived from EUR and finally, one for FX-swap implied rates derived from CAD. Libor submitters may be using smoothing techniques (which are permissible) to dampen the volatility of FX-swap implied rates.


Appendix

Figure A1: Overnight Liquidity Services for the U.S. Treasury




Source: Federal Reserve, Credit Suisse

Figure A2: Overnight Liquidity Services for Foreign Central Banks




Source: Federal Reserve, Credit Suisse

Figure A3: Overnight Liquidity Services for Money Market Funds



Source: Federal Reserve, Credit Suisse


Figure A4: Overnight Liquidity Services for Central Counterparties



Source: Federal Reserve, Credit Suisse

Figure A5: Sterilization and the Cross-Currency Basis (1)


\$ billion (LHS) and basis points (RHS)



Source: the BLOOMBERG PROFESSIONAL™ service, Federal Reserve, Credit Suisse

Figure A6: Sterilization and the Cross Currency Basis (2)

Reserves sterilized (\$ billion, x-axis) and the average of the €/¥ and \$/¥ cross-currency (bps, y-axis)



Source: the BLOOMBERG PROFESSIONAL™ service, Federal Reserve, Credit Suisse

GLOBAL FIXED INCOME AND ECONOMIC RESEARCH

James Sweeney, Managing Director
 Head of Fixed Income and Economic Research
 +1 212 538 4648
 james.sweeney@credit-suisse.com

Dr. Neal Soss, Managing Director
 Vice Chairman, Fixed Income Research
 1 212 325 3335
 neal.soss@credit-suisse.com

US / GLOBAL ECONOMICS AND STRATEGY

James Sweeney Chief Economist +1 212 538 4648 james.sweeney@credit-suisse.com	Xiao Cui +1 212 538 2511 xiao.cui@credit-suisse.com	Zoltan Pozsar +1 212 538 3779 zoltan.pozsar@credit-suisse.com	Melissa Pumphrey +1 212 538 4211 melissa.pumphrey@credit-suisse.com	Jeremy Schwartz +1 212 538 6419 jeremy.schwartz@credit-suisse.com	Wenzhe Zhao +1 212 325 1798 wenzhe.zhao@credit-suisse.com
---	--	--	--	--	--

Praveen Korapaty Head of Interest Rate Strategy 212 325 3427 praveen.korapaty@credit-suisse.com	Jonathan Cohn 212 325 4923 jonathan.cohn@credit-suisse.com
---	---

EUROPEAN ECONOMICS AND STRATEGY

Neville Hill Head of European Economics & Strategy +44 20 7888 1334 neville.hill@credit-suisse.com	Anais Boussie +44 20 7883 9639 anais.boussie@credit-suisse.com	Peter Foley +44 20 7883 4349 peter.foley@credit-suisse.com	Sonali Punhani +44 20 7883 4297 sonali.punhani@credit-suisse.com	Veronika Roharova +44 20 7888 2403 veronika.roharova@credit-suisse.com	Giovanni Zanni +44 20 7888 6827 giovanni.zanni@credit-suisse.com
--	---	---	---	---	---

David Sneddon Head of Technical Analysis 44 20 7888 7173 david.sneddon@credit-suisse.com	Christopher Hine 212 538 5727 christopher.hine@credit-suisse.com
--	---

GLOBAL FX / EM ECONOMICS AND STRATEGY

Shahab Jalinoos Head of Global FX Strategy 212 325 5412 shahab.jalinoos@credit-suisse.com	Honglin Jiang 44 20 7888 1501 honglin.jiang@credit-suisse.com	Trang Thuy Le +852 2101 7426 trangthuy.le@credit-suisse.com	Alvise Marino 212 325 5911 alvise.marino@credit-suisse.com	Bhaveer Shah 44 20 7883 1449 bhaveer.shah@credit-suisse.com
---	--	--	---	--

Kasper Bartholdy Head of Global EM Strategy +44 20 7883 4907 kasper.bartholdy@credit-suisse.com	Ashish Agrawal +65 6212 3405 ashish.agrawal@credit-suisse.com	Daniel Chodos +1 212 325 7708 daniel.chodos@credit-suisse.com	Nimrod Mevorach +44 20 7888 1257 nimrod.mevorach@credit-suisse.com
---	--	--	---

Berna Bayazitoglu Head of EEMEA Economics +44 20 7883 3431 berna.bayazitoglu@credit-suisse.com	Alexey Pogorelov +44 20 7883 0396 alexey.pogorelov@credit-suisse.com	Carlos Teixeira +27 11 012 8054 carlos.teixeira@credit-suisse.com
--	---	--

Alonso Cervera Head of Latin America Economics +52 55 5283 3845 alonso.cervera@credit-suisse.com	Juan Lorenzo Maldonado +1 212 325 4245 juanlorenzo.maldonado@credit-suisse.com	Casey Reckman +1 212 325 5570 casey.reckman@credit-suisse.com	Alberto Rojas +52 55 5283 8975 alberto.rojas@credit-suisse.com
--	---	--	---

Nilson Teixeira Head of Brazil Economics +55 11 3701 6288 nilson.teixeira@credit-suisse.com	Paulo Coutinho +55 11 3701-6353 paulo.coutinho@credit-suisse.com	Iana Ferrao +55 11 3701 6345 iana.ferrao@credit-suisse.com	Leonardo Fonseca +55 11 3701 6348 leonardo.fonseca@credit-suisse.com	Lucas Vilela +55 11 3701-6352 lucas.vilela @credit-suisse.com
---	---	---	---	--

ASIA PACIFIC DIVISION

Ray Farris, Managing Director
 Head of Fixed Income Research and Economics, Asia Pacific Division
 +65 6212 3412
 ray.farris@credit-suisse.com

EMERGING ASIA ECONOMICS

Dr. Santitarn Sathirathai Head of Emerging Asia Economics +65 6212 5675 santitarn.sathirathai@credit-suisse.com	Vincent Chan Head of China Macro +852 2101 6568 vincent.chan@credit-suisse.com	Deepali Bhargava +65 6212 5699 deepali.bhargava@credit-suisse.com	Weishen Deng +852 2101 7162 weishen.deng@credit-suisse.com	Michael Wan +65 6212 3418 michael.wan@credit-suisse.com
---	--	--	---	--

JAPAN ECONOMICS

Hirokichi Shirakawa Head of Japan Economics +81 3 4550 7117 hirokichi.shirakawa@credit-suisse.com	Takashi Shiono +81 3 4550 7189 takashi.shiono@credit-suisse.com
---	--

Disclosure Appendix

Analyst Certification

I, Zoltan Pozsar, certify that (1) the views expressed in this report accurately reflect my personal views about all of the subject companies and securities and (2) no part of my compensation was, is or will be directly or indirectly related to the specific recommendations or views expressed in this report.

Important Disclosures

Credit Suisse's research reports are made available to clients through our proprietary research portal on CS PLUS. Credit Suisse research products may also be made available through third-party vendors or alternate electronic means as a convenience. Certain research products are only made available through CS PLUS. The services provided by Credit Suisse's analysts to clients may depend on a specific client's preferences regarding the frequency and manner of receiving communications, the client's risk profile and investment, the size and scope of the overall client relationship with the Firm, as well as legal and regulatory constraints. To access all of Credit Suisse's research that you are entitled to receive in the most timely manner, please contact your sales representative or go to <https://plus.credit-suisse.com>.

Credit Suisse's policy is only to publish investment research that is impartial, independent, clear, fair and not misleading. For more detail, please refer to Credit Suisse's Policies for Managing Conflicts of Interest in connection with Investment Research: <https://www.credit-suisse.com/sites/disclaimers-ib/en/managing-conflicts.html>.

Credit Suisse's policy is to publish research reports as it deems appropriate, based on developments with the subject issuer, the sector or the market that may have a material impact on the research views or opinions stated herein.

The analyst(s) involved in the preparation of this research report received compensation that is based upon various factors, including Credit Suisse's total revenues, a portion of which are generated by Credit Suisse's Investment Banking and Fixed Income Divisions.

Credit Suisse currently has, or had within the past 12 months, the following as investment banking client(s): (JPMorganChase Bank)

Credit Suisse provided investment banking services to the subject issuer (JPMorganChase Bank) within the past 12 months.

Within the past 12 months, Credit Suisse has received compensation for investment banking services from the following issuer(s): (JPMorganChase Bank)

Credit Suisse expects to receive or intends to seek investment banking related compensation from the subject issuer (JPMorganChase Bank) within the next 3 months.

Credit Suisse has managed or co-managed a public offering of securities for the subject issuer (JPMorganChase Bank) within the past 12 months.

Credit Suisse may trade as principal in the securities or derivatives of the issuers that are the subject of this report.

A member of the Credit Suisse Group is party to an agreement with, or may have provided services set out in sections A and B of Annex I of Directive 2014/65/EU of the European Parliament and Council ("MiFID Services") to, the subject issuer (JPMorganChase Bank) within the past 12 months.

At any point in time, Credit Suisse is likely to have significant holdings in the securities mentioned in this report.

As at the date of this report, Credit Suisse acts as a market maker or liquidity provider in the debt securities of the subject issuer(s) mentioned in this report.

Important disclosures regarding companies or other issuers that are the subject of this report are available on Credit Suisse's disclosure website at <https://rave.credit-suisse.com/disclosures/view/fixedincome> or by calling +1 (877) 291-2683.

For the history of trade ideas suggested by the Fixed Income Research department over the previous 12 months, please view the document at <https://plus.credit-suisse.com/r/aaCzfz>. Credit Suisse clients with access to the Locus website may refer to <http://www.credit-suisse.com/locus>. For the history of trade ideas suggested by Emerging Markets Strategy Research, please see the latest *Emerging Markets Strategy Weekly* report on [Credit Suisse PLUS](#).

For the history of recommendations provided by Technical Analysis, please visit the website at https://plus.credit-suisse.com/ECP_S/app/container.html#loc=MENU_FI_ECON_TECHNICAL_ANALYSIS.

Credit Suisse does not provide any tax advice. Any statement herein regarding any US federal tax is not intended or written to be used, and cannot be used, by any taxpayer for the purposes of avoiding any penalties.

For a history of recommendations for the financial instrument(s) featured in this report, disseminated within the past 12 months, please refer to <https://rave.credit-suisse.com/disclosures/view/reportfi?i=298209&v=2rrccukek5rqztp2450qwyw7n>.

This research report is authored by:

Credit Suisse Securities (USA) LLC Zoltan Pozsar

Structured Securities, Derivatives, Options, and Futures Disclaimer

General risks: Structured securities, derivatives, options (OTC and listed), and futures (including, but not limited to, commodity, foreign exchange, and security futures) are complex instruments that are not suitable for every investor, may involve a high degree of risk, may be highly illiquid, and may be appropriate investments only for sophisticated investors who are capable of understanding and assuming the risks involved. **There is a risk of unlimited, total, or significant loss resulting from the use of these instruments for trading and investment.**

Before entering into any transaction involving these instruments, you should ensure that you fully understand their potential risks and rewards and independently determine that they are appropriate for you given your objectives, experience, financial and operational resources, and other relevant circumstances. For options, please ensure that you have read the Options Clearing Corporation's disclosure document, available at: <http://www.optionsclearing.com/publications/risks/riskchap1.jsp>.

Risk of losses on options: The maximum potential loss on buying a call or put option is the loss of total premium paid. The maximum potential loss on selling a call option is unlimited. The maximum potential loss on selling a put option is substantial and may exceed the premium received by a significant amount. There are many other options combinations that entail significant risks and transaction costs: you should ensure they are appropriate for your situation and that you understand the risks.

Risk of losses on futures: The maximum potential loss on buying a futures contract is substantial (the loss of the value of the contract) and can be amplified by leverage. The maximum potential loss on selling a futures contract is unlimited.

OTC options and other derivatives: In discussions of OTC options and other derivatives, the results and risks are based solely on the hypothetical examples cited; actual results and risks will vary depending on specific circumstances. Investors are urged to consider carefully whether these products, as well as the products or strategies discussed herein, are suitable to their needs. While some OTC markets may be liquid, transactions in OTC derivatives may involve greater risk than investments in exchange-listed derivatives because there is no exchange market on which to liquidate a position and it may be very difficult to assess the value of the position because bid and offer prices need not be quoted.

Structured products: These products often have a derivative component. As a result, they carry not only the risk of loss of principal, but also the possibility that at expiration the investor will own the reference asset at a depressed price. Even if a structured product is listed on an exchange, active and liquid trading markets may not develop and the structured product may be thinly traded.

Taxation: Because of the importance of tax considerations for many option and other derivative transactions, investors considering these products should consult with their tax advisors as to how taxes affect the outcome of contemplated options or other derivatives transactions. You should consult with such tax, accounting, legal or other advisors as you deem necessary to assist you in making these determinations.

Transaction costs: Such costs may be significant in option strategies calling for multiple purchases and sales of options and other derivatives, such as spreads and straddles. Commissions and transaction costs may be a factor in actual returns realized by the investor and should be taken into consideration.

Trading on margin: Margin requirements vary and should be determined before investing as they can impact your profit potential. If the market moves against your position, you may be called upon by your broker to deposit a substantial amount of additional margin funds, on short notice, in order to maintain your position. If you do not provide the required funds within the time required by your broker, your position may be liquidated at a loss, and you will be liable for any resulting deficit in your account.

Further information: Supporting documentation for any claims, comparisons, recommendations, statistics or other technical data in this material will be supplied upon request. Any trade information is preliminary and not intended as an official transaction confirmation. If you have any questions about whether you are eligible to enter into these transactions with Credit Suisse, please contact your sales representative.

This report is produced by subsidiaries and affiliates of Credit Suisse operating under its Global Markets Division. For more information on our structure, please use the following link: <https://www.credit-suisse.com/who-we-are>. This report may contain material that is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation or which would subject Credit Suisse or its affiliates ("CS") to any registration or licensing requirement within such jurisdiction. All material presented in this report, unless specifically indicated otherwise, is under copyright to CS. None of the material, nor its content, nor any copy of it, may be altered in any way, transmitted to, copied or distributed to any other party, without the prior express written permission of CS. All trademarks, service marks and logos used in this report are trademarks or service marks or registered trademarks or service marks of CS or its affiliates. The information, tools and material presented in this report are provided to you for information purposes only and are not to be used or considered as an offer or the solicitation of an offer to sell or to buy or subscribe for securities or other financial instruments. CS may not have taken any steps to ensure that the securities referred to in this report are suitable for any particular investor. CS will not treat recipients of this report as its customers by virtue of their receiving this report. The investments and services contained or referred to in this report may not be suitable for you and it is recommended that you consult an independent investment advisor if you are in doubt about such investments or investment services. Nothing in this report constitutes investment, legal, accounting or tax advice, or a representation that any investment or strategy is suitable or appropriate to your individual circumstances, or otherwise constitutes a personal recommendation to you. CS does not advise on the tax consequences of investments and you are advised to contact an independent tax advisor. Please note in particular that the bases and levels of taxation may change. Information and opinions presented in this report have been obtained or derived from sources believed by CS to be reliable, but CS makes no representation as to their accuracy or completeness. CS accepts no liability for loss arising from the use of the material presented in this report, except that this exclusion of liability does not apply to the extent that such liability arises under specific statutes or regulations applicable to CS. This report is not to be relied upon in substitution for the exercise of independent judgment. CS may have issued, and may in the future issue, other communications that are inconsistent with, and reach different conclusions from, the information presented in this report. Those communications reflect the different assumptions, views and analytical methods of the analysts who prepared them and CS is under no obligation to ensure that such other communications are brought to the attention of any recipient of this report. Some investments referred to in this report will be offered solely by a single entity and in the case of some investments solely by CS, or an associate of CS or CS may be the only market maker in such investments. Past performance should not be taken as an indication or guarantee of future performance, and no representation or warranty, express or implied, is made regarding future performance. Information, opinions and estimates contained in this report reflect a judgment at its original date of publication by CS and are subject to change without notice. The price, value of and income from any of the securities or financial instruments mentioned in this report can fall as well as rise. The value of securities and financial instruments is subject to exchange rate fluctuation that may have a positive or adverse effect on the price or income of such securities or financial instruments. Investors in securities such as ADRs, the values of which are influenced by currency volatility, effectively assume this risk. Structured securities are complex instruments, typically involve a high degree of risk and are intended for sale only to sophisticated investors who are capable of understanding and assuming the risks involved. The market value of any structured security may be affected by changes in economic, financial and political factors (including, but not limited to, spot and forward interest and exchange rates), time to maturity, market conditions and volatility, and the credit quality of any issuer or reference issuer. Any investor interested in purchasing a structured product should conduct their own investigation and analysis of the product and consult with their own professional advisers as to the risks involved in making such a purchase. Some investments discussed in this report may have a high level of volatility. High volatility investments may experience sudden and large falls in their value causing losses when that investment is realised. Those losses may equal your original investment. Indeed, in the case of some investments the potential losses may exceed the amount of initial investment and, in such circumstances, you may be required to pay more money to support those losses. Income yields from investments may fluctuate and, in consequence, initial capital paid to make the investment may be used as part of that income yield. Some investments may not be readily realisable and it may be difficult to sell or realise those investments, similarly it may prove difficult for you to obtain reliable information about the value, or risks, to which such an investment is exposed. This report may provide the addresses of, or contain hyperlinks to, websites. Except to the extent to which the report refers to website material of CS, CS has not reviewed any such site and takes no responsibility for the content contained therein. Such address or hyperlink (including addresses or hyperlinks to CS's own website material) is provided solely for your convenience and information and the content of any such website does not in any way form part of this document. Accessing such website or following such link through this report or CS's website shall be at your own risk.

This report is issued and distributed in **European Union (except Switzerland)**: by Credit Suisse Securities (Europe) Limited, One Cabot Square, London E14 4QJ, England, which is authorised by the Prudential Regulation Authority and regulated by the Financial Conduct Authority and the Prudential Regulation Authority. **Germany**: Credit Suisse Securities (Europe) Limited Niederlassung Frankfurt am Main regulated by the Bundesanstalt fuer Finanzdienstleistungsaufsicht ("BaFin"). **United States and Canada**: Credit Suisse Securities (USA) LLC; **Switzerland**: Credit Suisse AG; **Brazil**: Banco de Investimentos Credit Suisse (Brasil) S.A or its affiliates; **Mexico**: Banco Credit Suisse (México), S.A. (transactions related to the securities mentioned in this report will only be effected in compliance with applicable regulation); **Japan**: by Credit Suisse Securities (Japan) Limited, Financial Instruments Firm, Director-General of Kanto Local Finance Bureau (Kinsho) No. 66, a member of Japan Securities Dealers Association, The Financial Futures Association of Japan, Japan Investment Advisers Association, Type II Financial Instruments Firms Association; **Hong Kong**: Credit Suisse (Hong Kong) Limited; **Australia**: Credit Suisse Equities (Australia) Limited; **Thailand**: Credit Suisse Securities (Thailand) Limited, regulated by the Office of the Securities and Exchange Commission, Thailand, having registered address at 990 Abdulrahman Place, 27th Floor, Unit 2701, Rama IV Road, Silom, Bangkok, Bangkok10500, Thailand, Tel. +66 2614 6000; **Malaysia**: Credit Suisse Securities (Malaysia) Sdn Bhd; **Singapore**: Credit Suisse AG, Singapore Branch; **India**: Credit Suisse Securities (India) Private Limited (CIN no.U67120MH1996PTC104392) regulated by the Securities and Exchange Board of India as Research Analyst (registration no. INH 000001030) and as Stock Broker (registration no. INB230970637; INF230970637; INF010970631), having registered address at 9th Floor, Ceejay House, Dr.A.B. Road, Worli, Mumbai - 18, India, T- +91-22 6777 3777; **South Korea**: Credit Suisse Securities (Europe) Limited, Seoul Branch; **Taiwan**: Credit Suisse AG Taipei Securities Branch; **Indonesia**: PT Credit Suisse Sekuritas Indonesia; **Philippines**: Credit Suisse Securities (Philippines) Inc., and elsewhere in the world by the relevant authorised affiliate of the above.

Additional Regional Disclaimers

Hong Kong: Credit Suisse (Hong Kong) Limited ("CSHK") is licensed and regulated by the Securities and Futures Commission of Hong Kong under the laws of Hong Kong, which differ from Australian laws. CSHK does not hold an Australian financial services licence (AFSL) and is exempt from the requirement to hold an AFSL under the Corporations Act 2001 (the Act) under Class Order 03/1103 published by the ASIC in respect of financial services provided to Australian wholesale clients (within the meaning of section 761G of the Act). Research on Taiwanese securities produced by Credit Suisse AG, Taipei Securities Branch has been prepared by a registered Senior Business Person.

Australia (to the extent services are offered in Australia): Credit Suisse Securities (Europe) Limited ("CSSEL") and Credit Suisse International ("CSI") are authorised by the Prudential Regulation Authority and regulated by the Financial Conduct Authority ("FCA") and the Prudential Regulation Authority under UK laws, which differ from Australian Laws. CSSEL and CSI do not hold an Australian Financial Services Licence ("AFSL") and are exempt from the requirement to hold an AFSL under the Corporations Act (Cth) 2001 ("Corporations Act") under Class Order 03/1099 published by the Australian Securities and Investments Commission ("ASIC"), in respect of the financial services provided to Australian wholesale clients (within the meaning of section 761G of the Corporations Act). This material is not for distribution to retail clients and is directed exclusively at Credit Suisse's professional clients and eligible counterparties as defined by the FCA, and wholesale clients as defined under section 761G of the Corporations Act. Credit Suisse (Hong Kong) Limited ("CSHK") is licensed and regulated by the Securities and Futures Commission of Hong Kong under the laws of Hong Kong, which differ from Australian laws. CSHK does not hold an AFSL and is exempt from the requirement to hold an AFSL under the Corporations Act under Class Order 03/1103 published by the ASIC in respect of financial services provided to Australian wholesale clients (within the meaning of section 761G of the Corporations Act). Credit Suisse Securities (USA) LLC (CSSU) and Credit Suisse Asset Management LLC (CSAM LLC) are licensed and regulated by the Securities Exchange Commission of the United States under the laws of the United States, which differ from Australian laws. CSSU and CSAM LLC do not hold an AFSL and is exempt from the requirement to hold an AFSL under the Corporations Act under Class Order 03/1100 published by the ASIC in respect of financial services provided to Australian wholesale clients (within the meaning of section 761G of the Corporations Act).

Malaysia: Research provided to residents of Malaysia is authorised by the Head of Research for Credit Suisse Securities (Malaysia) Sdn Bhd, to whom they should direct any queries on +603 2723 2020.

Singapore: This report has been prepared and issued for distribution in Singapore to institutional investors, accredited investors and expert investors (each as defined under the Financial Advisers Regulations) only, and is also distributed by Credit Suisse AG, Singapore Branch to overseas investors (as defined under the Financial Advisers Regulations). Credit Suisse AG, Singapore Branch may distribute reports produced by its foreign entities or affiliates pursuant to an arrangement under Regulation 32C of the Financial Advisers Regulations. Singapore recipients should contact Credit Suisse AG, Singapore Branch at +65-6212-2000 for matters arising from, or in connection with, this report. By virtue of your status as an institutional investor, accredited investor, expert investor or overseas investor, Credit Suisse AG, Singapore Branch is exempted from complying with certain compliance requirements under the Financial Advisers Act, Chapter 110 of Singapore (the "FAA"), the Financial Advisers Regulations and the relevant Notices and Guidelines issued thereunder, in respect of any financial advisory service which Credit Suisse AG, Singapore Branch may provide to you.

UAE: This information is being distributed by Credit Suisse AG (DIFC Branch), duly licensed and regulated by the Dubai Financial Services Authority ("DFSA"). Related financial services or products are only made available to Professional Clients or Market Counterparties, as defined by the DFSA, and are not intended for any other persons. Credit Suisse AG (DIFC Branch) is located on Level 9 East, The Gate Building, DIFC, Dubai, United Arab Emirates.

EU: This report has been produced by subsidiaries and affiliates of Credit Suisse operating under its Global Markets Division

In jurisdictions where CS is not already registered or licensed to trade in securities, transactions will only be effected in accordance with applicable securities legislation, which will vary from jurisdiction to jurisdiction and may require that the trade be made in accordance with applicable exemptions from registration or licensing requirements. Non-US customers wishing to effect a transaction should contact a CS entity in their local jurisdiction unless governing law permits otherwise. US customers wishing to effect a transaction should do so only by contacting a representative at Credit Suisse Securities (USA) LLC in the US.

Please note that this research was originally prepared and issued by CS for distribution to their market professional and institutional investor customers. Recipients who are not market professional or institutional investor customers of CS should seek the advice of their independent financial advisor prior to taking any investment decision based on this report or for any necessary explanation of its contents. This research may relate to investments or services of a person outside of the UK or to other matters which are not authorised by the Prudential Regulation Authority and regulated by the Financial Conduct Authority and the Prudential Regulation Authority or in respect of which the protections of the Prudential Regulation Authority and Financial Conduct Authority for private customers and/or the UK compensation scheme may not be available, and further details as to where this may be the case are available upon request in respect of this report.

CS may provide various services to US municipal entities or obligated persons ("municipalities"), including suggesting individual transactions or trades and entering into such transactions. Any services CS provides to municipalities are not viewed as "advice" within the meaning of Section 975 of the Dodd-Frank Wall Street Reform and Consumer Protection Act. CS is providing any such services and related information solely on an arm's length basis and not as an advisor or fiduciary to the municipality. In connection with the provision of the any such services, there is no agreement, direct or indirect, between any municipality (including the officials, management, employees or agents thereof) and CS for CS to provide advice to the municipality. Municipalities should consult with their financial, accounting and legal advisors regarding any such services provided by CS. In addition, CS is not acting for direct or indirect compensation to solicit the municipality on behalf of an unaffiliated broker, dealer, municipal securities dealer, municipal advisor, or investment adviser for the purpose of obtaining or retaining an engagement by the municipality for or in connection with Municipal Financial Products, the issuance of municipal securities, or of an investment adviser to provide investment advisory services to or on behalf of the municipality. If this report is being distributed by a financial institution other than Credit Suisse AG, or its affiliates, that financial institution is solely responsible for distribution. Clients of that institution should contact that institution to effect a transaction in the securities mentioned in this report or require further information. This report does not constitute investment advice by Credit Suisse to the clients of the distributing financial institution, and neither Credit Suisse AG, its affiliates, and their respective officers, directors and employees accept any liability whatsoever for any direct or consequential loss arising from their use of this report or its content. Principal is not guaranteed. Commission is the commission rate or the amount agreed with a customer when setting up an account or at any time after that.

Copyright © 2017 CREDIT SUISSE AG and/or its affiliates. All rights reserved.

Investment principal on bonds can be eroded depending on sale price or market price. In addition, there are bonds on which investment principal can be eroded due to changes in redemption amounts. Care is required when investing in such instruments.

When you purchase non-listed Japanese fixed income securities (Japanese government bonds, Japanese municipal bonds, Japanese government guaranteed bonds, Japanese corporate bonds) from CS as a seller, you will be requested to pay the purchase price only.